Heparin is introduced in cardiac patient with pregnancy: (AIIMS Nov 2012)
|D||At the time of labour|
Heparin is the drug of choice for anticoagulant action during pregnancy.
For patients at risk of thromboembolism and those who have prosthetic heart valves, guidelines from the American College of Chest Physicians (ACCP) consensus on antithrombotic therapy recommend one of three regimens:
a. Aggressive adjusted-dose low molecular weight heparin (LMWH) throughout pregnancy with monitoring of anti Xa levels;
b. Adjusted-dose subcutaneous UFH throughout pregnancy with monitoring of the aPTT;
c. Use of either subcutaneous LMWH or UFH between 6 and 12 weeks and close to term (i.e., at week 36 and thereafter)